Compare · GRTX vs STOK
GRTX vs STOK
Side-by-side comparison of Galera Therapeutics Inc. (GRTX) and Stoke Therapeutics Inc. (STOK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GRTX and STOK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- STOK is the larger of the two at $2.16B, about 32.7x GRTX ($66.1M).
- STOK has been more active in the news (15 items in the past 4 weeks vs 12 for GRTX).
- STOK has more recent analyst coverage (18 ratings vs 7 for GRTX).
- Company
- Galera Therapeutics Inc.
- Stoke Therapeutics Inc.
- Price
- $0.15-32.96%
- $32.97-1.38%
- Market cap
- $66.1M
- $2.16B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2019
- News (4w)
- 12
- 15
- Recent ratings
- 7
- 18
Galera Therapeutics Inc.
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Stoke Therapeutics Inc.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Latest GRTX
- SEC Form EFFECT filed by Galera Therapeutics Inc.
- President and CEO Sorensen Mel returned 975 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- SEC Form 4 filed by Director Lokay Kevin G (tax liability)
- Director Chang Nancy T converted options into 661,309 shares and returned 47,434 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Director Alleva Lawrence M returned 51 shares to the company, closing all direct ownership in the company (SEC Form 4) (for tax liability)
- SEC Form 4 filed by Chief Accounting Officer Sussman Joel F. (withholding obligation)
- Director Friedman Michael R. converted options into 2,989,399 shares and returned 41,631 shares to the company (SEC Form 4) (tax withholding)
- SEC Form 15-12G filed by Galera Therapeutics Inc.
- SEC Form POS AM filed by Galera Therapeutics Inc.
- SEC Form S-8 POS filed by Galera Therapeutics Inc.
Latest STOK
- Analyst resumed coverage on Stoke Therapeutics with a new price target
- CHIEF MEDICAL OFFICER Ticho Barry converted options into 10,000 shares and sold $152,690 worth of shares (4,767 units at $32.03), increasing direct ownership by 26% to 25,655 units (SEC Form 4) to satisfy withholding tax
- Director Kaye Edward M. Md converted options into 26,250 shares and sold $402,528 worth of shares (12,567 units at $32.03), increasing direct ownership by 12% to 124,557 units (SEC Form 4) to satisfy withholding obligation
- GENERAL COUNSEL & CORP SEC Allan Jonathan converted options into 6,000 shares and sold $91,639 worth of shares (2,861 units at $32.03), increasing direct ownership by 17% to 21,225 units (SEC Form 4) (tax withholding)
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.
- CHIEF MEDICAL OFFICER Ticho Barry sold $208,385 worth of shares (7,176 units at $29.04) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 20,422 units (SEC Form 4)
- Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
- SEC Form 8-K filed by Stoke Therapeutics Inc.